Abstract:Abstract Background: Protein phosphatase 2A (PP2A) has been shown to be an important tumor suppressor protein and loss of PP2A function has been identified in several solid cancers and in leukemias. Recent studies have suggested strategies for enhancing PP2A activity as an anti-leukemic approach. Among the potential key players regulating PP2A, a new oncoprotein, called cancerous inhibitor of protein phosphatase 2A (CIP2A), is recently identified as a key factor in the development of malignancies in various human cells. Previously we studied novel drug mechanisms of bortezomib, a proteasome inhibitor, on acute leukemia cells. We discovered that CIP2A plays an indispensable role in mediating bortezomib-induced apoptosis in acute leukemia cells (Hematologica 2013), hepatocellular carcinoma cells (Oncogene 2010) and in breast cancer cells (Breast Cancer Research 2012). Importantly, this mechanism by bortezomib is independent to its proteasome inhibition. Carfilzomib, a more selective proteasome inhibitor than bortezomib, has shown efficacy in multiple myeloma and is being investigated in phase III clinical trials. In this study, we examined the effect of carfilzomib on CIP2A in leukemia cells. Methods: Leukemia cell lines (HL-60, KG-1, THP-1, and K562) were used for in vitro studies. Apoptosis was examined by both flow cytometry and Western blot. Signal transduction pathways in cells were assessed by Western Blot. Quantitative RT-PCR was used for assessing gene transcription. In vivo efficacy of carfilzomib was tested in nude mice with subcutaneous leukemia xenografts. Results: We found carfilzomib induced differential antiproliferative effects and apoptosis. HL-60, KG-1 and THP-1, but not K562 cells, were sensitive to carfilzomib-induced apoptosis. Similarly, carfilzomib-induced apoptosis may be dissociated with its proteasome inhibition. We found CIP2A mediated this apoptotic effect of carfilzomib in leukemia cells. Carfilzomib down-regulated CIP2A in association with p-Akt downregulation. Furthermore, carfilzomib increased PP2A activity and over-expression of CIP2A up-regulated p-Akt and suppressed carfilzomib-induced apoptosis. In addition, carfilzomib downregulated CIP2A mRNA but did not affect the degradation of CIP2A protein. Further dissecting the regulatory mechanism showed that carfilzomib may affect CIP2A transcription though transcriptional factors. Importantly, carfilzomib demonstrated anti-tumor activity in xenografted mice models. Conclusions: CIP2A is a major determinant mediating carfilzomib-induced apoptosis in leukemia cells and may be a therapeutic target in leukemia. This study disclosed a novel drug mechanism of carfilzomib in leukemia cells. (Supported by Taiwan Clinical Oncology Research Foundation, MOST 103-2325-B-075-002, V103C-141; and TVGH-NTUH Joint Research Program VN103-08) Citation Format: Chun-Yu Liu, Wen-Chun Tsai, Man-Hsin Hung, Yuan-Bin Yu, Po-Shen Ko, Cheng-Hwai Tzeng, Chung-Wai Shiau, Kuen-Feng Chen. Carfilzomib transcriptionally regulates CIP2A/PP2A/p-Akt signaling and induces apoptosis in leukemia cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1737. doi:10.1158/1538-7445.AM2015-1737

Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells.

Carfilzomib inhibits cell cycle progression at G 2 / M phase and induces apoptosis in breast cancer cells

HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer

Resistance of Osteosarcoma Cells to the Proapoptotic Effects of Carfilzomib Involves Activation of Mitogen Activated Protein Kinase Pathways

A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma

Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.

Proteasome Inhibitor Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitor Vorinostat in Jurkat T-leukemia Cells

Carfilzomib induces G2/M cell cycle arrest in human endometrial cancer cells via upregulation of p21Waf1/Cip1 and p27Kip1.

Carfilzomib activates ER stress and JNK/p38 MAPK signaling to promote apoptosis in hepatocellular carcinoma cells

Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells Via Modulation of Ros Generation and Erk1/2

Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer.

Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis

Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.

Delanzomib, A Novel Proteasome Inhibitor, Sensitizes Breast Cancer Cells To Doxorubicin-Induced Apoptosis

Carfilzomib inhibits the proliferation and apoptosis of multiple myeloma cells by inhibiting STAT1/COX-2/iNOS signaling pathway

Abstract 1737: Carfilzomib Transcriptionally Regulates CIP2A/PP2A/p-Akt Signaling and Induces Apoptosis in Leukemia Cells

Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib

Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma

Short-Term Proteasome Inhibition: Assessment of the Effects of Carfilzomib and Bortezomib on Cardiac Function, Arterial Stiffness, and Vascular Reactivity

Preclinical efficacy of carfilzomib in BRAF‐mutant colorectal cancer models